INVESTIGATION OF SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL EFFICACY OF ORAL DANIRIXIN IN SYMPTOMATIC COPD SUBJECTS WITH MILD TO MODERATE AIRFLOW LIMITATION AT RISK FOR EXACERBATIONS: